Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 100%. A quarter ago, it was expected that this pharmaceutical company would post a loss of $0.06 per share when it actually produced a loss of $0.02, delivering a surprise of 66.67%. Over the last four quarters, t ...

The Board of Governors of the Federal Reserve System (the Fed) adopted Regulation II in 2011, establishing fees for debit-card transactions. Corner Post began operating in 2018 and filed its lawsuit challenging Regulation II in 2021, claiming it had incurred excessive interchange fees under the rule. The U.S. Court of Appeals for the Eighth Circuit ruled that Corner Post's opportunity to file suit had expired in 2017, six years after the rule first issued. "Because an APA plaintiff may not file suit and obt ...

Core Viewpoint - The U.S. Court of Appeals for the Tenth Circuit has reversed a district court decision regarding warrantless searches of dog training businesses, indicating potential violations of the Fourth Amendment rights of the appellants [1]. Group 1: Legal Context - The New Civil Liberties Alliance (NCLA) filed an amicus curiae brief arguing that the Kansas state law allowing warrantless searches infringes on the Fourth Amendment rights of individuals [1]. - The Tenth Circuit affirmed the dismissal of the claim regarding the right to travel but remanded the case to determine the applicability of the Fourth Amendment to warrantless searches of dog training businesses [1][4]. Group 2: Case Background - Scott Johnson and Harlene Hoyt operate Covey Find Kennel, a licensed dog training business, which is subject to unannounced inspections under the Kansas Pet Animal Act [2]. - The law requires one of the owners to be present for inspections with only 30 minutes' notice, allowing the Kansas Department of Agriculture to conduct searches without probable cause [2]. Group 3: Court's Reasoning - The Tenth Circuit found insufficient information to determine if Covey Find Kennel is a "closely regulated" business exempt from Fourth Amendment protections, criticizing the district court's broad application of this exception [4]. - The court's decision prevents the potential for widespread intrusions across various regulated industries in Kansas [4]. Group 4: NCLA's Position - NCLA argues that applying the Fourth Amendment exception for closely regulated businesses to dog training facilities is unreasonable and should be rejected by the district court [5]. - NCLA emphasizes the need to protect constitutional rights from being overridden by state licensing requirements [3].

Washington, D.C., June 05, 2024 (GLOBE NEWSWIRE) -- Today, the U.S. Court of Appeals for the Fifth Circuit issued a decision in National Association of Private Fund Managers v. Securities and Exchange Commission vacating SEC's recent final rule restricting—and in some cases prohibiting—certain common contractual agreements between private investment funds and investment advisers. Following the New Civil Liberties Alliance amicus curiae brief's advice, the Court declared that SEC exceeded its statutory autho ...

PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the Galien Foundation has awarded the 2024 Prix Galien U.K. Award for Best Pharmaceutical Product to Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat). The prestigious Prix Galien is awarded to companies recognized for their outstanding advances in the discovery and devel ...

The company also markets Pombiliti + Opfolda, which was recently approved (October 2023) to treat adults with late-onset Pompe disease (LOPD). Management believes these two products have north of $1.5 billion peak sales potential combined. The stock trades for around $9.50 a share and has a market cap of just north of $2.8 billion. avdeev007 Today, we put rare disease concern Amicus Therapeutics (NASDAQ:FOLD) under the spotlight. The shares have recently slid under the $10 a share level, which seems too che ...

Amicus Therapeutics (FOLD) reported first-quarter 2024 adjusted loss of 2 cents per share, narrower than the Zacks Consensus Estimate of a loss of 6 cents. The company had incurred a loss of 6 cents per share in the year-ago quarter.The year-over-year improvement can be attributed to higher revenues from Galafold (migalastat) sales and incremental revenues from the sale of the newly approved combo drug, Pombiliti + Opfolda.Revenues in the reported quarter totaled $110.4 million, up 28% year over year on a r ...

For the quarter ended March 2024, Amicus Therapeutics (FOLD) reported revenue of $110.4 million, up 28% over the same period last year. EPS came in at -$0.02, compared to -$0.18 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $111.62 million, representing a surprise of -1.09%. The company delivered an EPS surprise of +66.67%, with the consensus EPS estimate being -$0.06.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33497 Amicus Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 71-0869350 (State or Other Juris ...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Martel - CBO Jeff Castelli - CDO Simon Harford - CFO Conference Call Participants Anupam Rama - JPMorgan Ellie Merle - UBS Kristen Kluska - Cantor Fitzgerald Tazeen Ahmad - Bank of America Operator Good morning ladies and gentlemen and welcome to the Amicus Therapeutics' First Quarter 2024 Financial Results Conference Cal ...